Irhythm Technologies ( (IRTC) ) has provided an announcement.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
iRhythm Technologies announced its preliminary fourth quarter 2024 highlights and business updates at the J.P. Morgan Healthcare Conference, indicating a strong year with revenues expected to exceed their guidance. The company achieved record account openings and expanded globally, securing FDA clearance for Zio device advancements, and initiated manufacturing automation, reflecting a commitment to growth and innovation. Looking forward, iRhythm plans to enhance its quality systems and further penetrate both domestic and international markets, focusing on sustainable value creation for stakeholders.
More about Irhythm Technologies
iRhythm Technologies, Inc. is a leading digital healthcare company that focuses on creating solutions to detect, predict, and prevent disease through wearable biosensors and cloud-based data analytics. The company is known for its Zio products, which provide clinically actionable insights from heart data, aiming to enhance patient care and health outcomes.
YTD Price Performance: 9.24%
Average Trading Volume: 488,446
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $3.06B
See more insights into IRTC stock on TipRanks’ Stock Analysis page.
